Cambridge, United Kingdom

Delphine Buffet

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Delphine Buffet: Innovator in Cancer Treatment

Introduction

Delphine Buffet is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biomedical research, particularly in the development of therapeutic agents for cancer and infectious diseases. Her innovative work has led to the filing of a patent that showcases her expertise and dedication to improving healthcare outcomes.

Latest Patents

Delphine Buffet holds a patent for "Fc binding fragments comprising an OX40 antigen-binding site." This patent relates to specific binding members that target OX40, a crucial component in the immune response. The specific binding members include an OX40 antigen-binding site located in a constant domain, which has potential applications in treating various cancers and infectious diseases.

Career Highlights

Throughout her career, Delphine has demonstrated a strong commitment to advancing medical science. Her work at Invox Pharma Limited has positioned her as a key player in the development of innovative therapies. With her extensive knowledge and experience, she continues to contribute to the field of immunotherapy.

Collaborations

Delphine collaborates with talented professionals in her field, including Mihriban Tuna and Miguel Gaspar. These partnerships enhance her research efforts and foster a collaborative environment that drives innovation.

Conclusion

Delphine Buffet is a trailblazer in the realm of biomedical innovation, with a focus on developing therapies that can significantly impact patient care. Her contributions to the field, particularly through her patent on OX40 binding fragments, highlight her role as a leading inventor in the fight against cancer and infectious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…